Simply Sit on That Sarepta Trade, and More Updates
Research - The NASDAQ Biotech Index Fund (IBB) failed to break out from $285 last week (discussed two weeks ago in our webinar) and subsequently lost key … Continue Reading
PremiumSearch Results for uniqure
Bluebird Bio’s CALD Data, And Other Updates
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
Premium
Stocks Start the New Year on the Wrong Foot
Insights - Biopharma stocks are starting the year off on absolutely the wrong foot (though so is everything else), and last night’s SEVEN secondary stock offerings didn’t help Wednesday's price action.
Premium
The Fed’s Rate Raise is Finally Behind Us
Research - The Fed announced Wednesday afternoon the first increase to the federal funds rate since 2006, to between 0.25% and 0.5%, and up from near-zero percent for the last seven years.
Premium
Let’s List All of the Events Impacting Sentiment for Equities…
Insights - The NASDAQ Biotech Index (NBI) ended the week on a low note – just 2 percentage points from giving back the entirety of its gains … Continue Reading
Read nowA September Market Update
Research - Last week was yet another exhausting, anemic few sessions in the markets. One day we're up, and the next we're down - with gaps nonetheless - but a trend is non-existent.
Premium
Coming Away From Second Quarter Earnings, Here’s What’s New in Biotech
Research - It’s been “risk-off” in equities this week as traders begin to factor in a rate hike from the Fed, and the high-beta biotech sector has … Continue Reading
Read now